Cubist beats handily. Revenues $5 million above consensus, eps ~10 cents above. Guidance to come on the CC. Here's another position that will probably be called away from me, though I wrote August series calls.
>>Cubist Pharmaceuticals Reports Second Quarter 2007 Results: Total Revenues $69.8 Million; Net Product Revenues $69.5 Million, +52% Vs. Q2 2006
Wednesday July 18, 4:01 pm ET
GAAP Basic and Diluted Net Income of $0.26 and $0.24 Per Share, Respectively
Non-GAAP Basic and Diluted Net Income of $0.31 and $0.28 Per Share, Respectively
Earnings Conference Call & Webcast Today (With Slides) at 5:00 pm EDT
LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST - News) today reported results for the second quarter ended June 30, 2007. Net sales of CUBICIN® (daptomycin for injection) increased 52% from the prior year, from $45.7 million in the second quarter of 2006 to $69.5 million in the second quarter of 2007. U.S. net product revenue was $68.3 million. Total revenues for the second quarter of 2007 increased 46% over the second quarter of 2006 from $47.8 million in the second quarter of 2006 to $69.8 million in the second quarter of 2007.
Net income for the second quarter ended June 30, 2007 on a GAAP basis was $14.5 million, or $0.26 and $0.24 per basic and diluted share, respectively, as compared to a net loss of $5.1 million, or $0.09 per basic and diluted share for the second quarter of 2006. Second quarter 2007 GAAP net income includes $2.7 million, or $0.05 and $0.04 per basic and diluted share, respectively, in stock-based compensation expenses as a result of our adoption on January 1, 2006 of Financial Accounting Standards No. 123® ("FAS 123®").
Non-GAAP net income for the second quarter ended June 30, 2007, excluding the charges mentioned above, was $17.2 million, or $0.31 and $0.28 per basic and diluted share, respectively.
As of June 30, 2007, Cubist had $352.8 million in cash, cash equivalents and investments. The total number of common shares outstanding at June 30, 2007 was 55,515,047.
Use of Non-GAAP Financial Measures
Cubist adopted FAS 123® on January 1, 2006 using the modified prospective method, which resulted in the recognition of stock-based compensation expenses in the statement of operations from 2006 onward without adjusting the prior years. Cubist uses non-GAAP net income (loss) and non-GAAP net income (loss) per share data to improve its analysis of operational results and trends. Cubist's management also uses these non-GAAP figures to make financial and operational decisions as these numbers exclude non-operational activities and because management believes these measures are useful to investors because they provide greater transparency regarding Cubist's operating performance. These measures should not be considered an alternative to measurements required by GAAP, such as net income (loss) and net income (loss) per share, and should not be considered measures of our liquidity. In addition, these non-GAAP measures are unlikely to be comparable with non-GAAP information provided by other companies. A reconciliation between non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this press release after the unaudited condensed consolidated financial statements.
***********CONFERENCE CALL & WEBCAST INFORMATION***********
Cubist will host a conference call and live audio webcast to
discuss its second quarter 2007
Financial results, business activities and financial outlook.
WHEN: Wednesday, July 18, 2007 at 5:00 p.m. EDT
LIVE DOMESTIC & CANADA CALL-IN: 877-407-0778
LIVE INTERNATIONAL CALL-IN: 201-689-8565
24-HOUR REPLAY DOMESTIC & CANADA: 877-660-6853
24-HOUR REPLAY INTERNATIONAL: 201-612-7415
REPLAY PASSCODES (BOTH REQUIRED FOR PLAYBACK):
ACCOUNT #: 286 CONFERENCE ID #: 240215
CALL WILL ALSO BE BROADCAST LIVE, LISTEN ONLY, VIA THE WEB AT:
www.cubist.com
Replay will be available for 30 days at www.cubist.com *******************************************************************
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN®(daptomycin for injection), the first antibiotic in a new class of anti-infective called lipopeptides. The Cubist product pipeline includes our lipopeptide program and our natural products screening program. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.
Cubist Safe Harbor Statement
Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and such statements are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cubist. These factors include, but are not limited to: (i) the level of acceptance of CUBICIN by physicians, patients, third-party payors and the medical community; (ii) any changes in the current or anticipated market demand or medical need for CUBICIN; (iii) any unexpected adverse events related to CUBICIN, particularly as CUBICIN is used in the treatment of a growing number of patients around the world; (iv) competition in the markets in which we and our partners market CUBICIN, including marketing approvals for new products that will be competitive with CUBICIN; (v) whether the U.S. Food and Drug Administration, or FDA, accepts proposed clinical trial protocols that may be achieved in a timely manner for additional studies of CUBICIN or any other drug candidate we seek to enter into clinical trials; (vi) whether we will receive, and the potential timing of, regulatory approvals or clearances to market CUBICIN in other countries; (vii) legislative and policy changes in the United States and other jurisdictions where our products are sold that may affect the ease of getting a new product or a new indication approved; (viii) changes in government reimbursement for our or our competitors' products; (ix) whether or not third parties may seek to market generic versions of our products by filing Abbreviated New Drug Applications, or ANDAs, with the FDA, and the results of any litigation that we file to defend and/or assert our patents against such generic companies; (x) our ability to conduct successful clinical trials in a timely manner; (xi) the effect that the results of ongoing or future clinical trials of CUBICIN may have on its acceptance in the medical community; (xii) the ability of our third party manufacturers, including our single source provider of active pharmaceutical ingredient, or API, to manufacture sufficient quantities of CUBICIN in accordance with Good Manufacturing Practices and other requirements of the regulatory approvals for CUBICIN and at an acceptable cost; (xiii) our dependence upon collaborations with our partners and our partners' ability to execute on development, regulatory and sales expectations in their territories; (xiv) our ability to finance our operations; (xv) the effectiveness of our sales force and our sales force's ability to access targeted physicians; (xvi) potential costs resulting from product liability or other third party claims; (xvii) our ability to protect our proprietary technologies; (xviii) our ability to integrate successfully the operations of any business that we may acquire and the potential impact of any future acquisition on our financial results; (xix) our ability to discover, acquire or in-license drug candidates and develop and achieve commercial success for drug candidates; and (xx) a variety of risks common to our industry, including ongoing regulatory review, public and investment community perception of the industry, legislative or regulatory changes, and our ability to attract and retain talented employees.
Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cubist's recent filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in such filings.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.
CUBIST PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED
(in thousands)
June 30, December
31,
2007 2006
-------- --------
ASSETS
Cash, cash equivalents and investments $352,765 $309,169
Accounts receivable, net 25,186 21,070
Inventory 14,009 18,111
Property and equipment, net 49,428 49,584
Other assets 38,516 41,101
-------- --------
Total assets $479,904 $439,035
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued expenses $38,129 $34,640
Deferred revenue 17,545 11,800
Debt and capital lease obligations 351,778 352,005
-------- --------
Total liabilities 407,452 398,445
-------- --------
Total stockholders' equity 72,452 40,590
-------- --------
Total liabilities and stockholders' equity $479,904 $439,035
======== ========
CUBIST PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED
(in thousands, except share and per share data)
Three months ended Six months ended
June 30, June 30,
--------------------- ---------------------
2007 2006 2007 2006
---------- ---------- ---------- ----------
Revenues:
U.S. product revenues,
net $68,294 $45,648 $125,819 $83,011
International product
revenues 1,231 33 3,141 611
Other revenues 239 2,113 283 4,227
---------- ---------- ---------- ----------
Total revenues, net $69,764 $47,794 $129,243 $87,849
Costs and expenses:
Cost of product revenues 15,834 11,790 32,572 21,922
Research and development 17,145 13,674 33,015 27,255
Sales and marketing 15,993 14,249 30,987 28,317
General and
administrative 7,787 6,607 15,507 13,275
---------- ---------- ---------- ----------
Total costs and
expenses 56,759 46,320 112,081 90,769
Operating income (loss) 13,005 1,474 17,162 (2,920)
---------- ---------- ---------- ----------
Other income (expense), net 2,007 (6,547) 3,617 (8,033)
---------- ---------- ---------- ----------
Income (loss) before income
taxes 15,012 (5,073) 20,779 (10,953)
Provision for income taxes 522 - 688 -
---------- ---------- ---------- ----------
Net income (loss) $14,490 $(5,073) $20,091 $(10,953)
========== ========== ========== ==========
Basic net income (loss) per
common share $0.26 $(0.09) $0.36 $(0.20)
Diluted net income (loss)
per common share $ 0.24(a) $(0.09) $ 0.35(a) $(0.20)
Shares used in calculating:
Basic net income (loss)
per common share 55,406,882 54,347,892 55,263,940 54,214,340
Diluted net income (loss)
per common share 68,754,256 54,347,892 68,554,427 54,214,340
(a) Includes add back of interest expense related to 2.25% notes to income, net of tax effect
CUBIST PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - NON-GAAP
UNAUDITED
(in thousands, except share and per share data)
Three months ended Six months ended
June 30, June 30,
--------------------- ---------------------
2007 2006 2007 2006
---------- ---------- ---------- ----------
GAAP net income (loss) $ 14,490 $(5,073) $20,091 $(10,953)
Stock-based compensation
expense under SFAS 123(R) 2,692 2,676 5,331 5,251
Debt prepayment penalty and
write off of deferred
issuance costs - 5,662 - 5,662
---------- ---------- ---------- ----------
Non-GAAP proforma net
income (loss) $ 17,182 $ 3,265 $25,422 $(40)
========== ========== ========== ==========
Non-GAAP basic net income
(loss) per common share $0.31 $0.06 $0.46 $(0.00)
Non-GAAP diluted net income
(loss) per common share $ 0.28(a) $0.06 $ 0.43(a) $(0.00)
Shares used in calculating:
Non-GAAP basic net income
(loss) per common share 55,406,882 54,347,892 55,263,940 54,214,340
Non-GAAP diluted net
income (loss) per common
share 68,754,256 54,347,892 68,554,427 54,214,340
(a) Includes add back of interest expense related to 2.25% notes to income, net of tax effect<<
Cheers, Tuck |
